Phase 1-ready biotech developing in-licensed precision therapies for cancer.
Industry: Health Care
Latest Trade: $6.31 0.00 (0.0%)
First Day Return: -35.0%
Return from IPO: +26.2%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 10/06/2021 |
Offer Price | $5.00 |
Price Range $5.00 - $7.00 | |
Offer Shares (mm) | 3.2 |
Deal Size ($mm) | $16 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 02/04/2022 |
Offer Price | $5.00 |
Price Range $5.00 - $7.00 | |
Offer Shares (mm) | 3.2 |
Deal Size ($mm) | $16 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
H.C. Wainwright |
Company Data | |
---|---|
Headquarters | Fort Lee, NJ, United States |
Founded | 2020 |
Employees at IPO | 6 |
Website www.nuvectis.com |